2,537 Shares in Glaukos Co. (NYSE:GKOS) Bought by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP bought a new stake in Glaukos Co. (NYSE:GKOS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,537 shares of the medical instruments supplier’s stock, valued at approximately $331,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in shares of Glaukos during the third quarter worth approximately $25,000. GAMMA Investing LLC boosted its position in Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 486 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos during the 2nd quarter worth $187,000. KBC Group NV increased its holdings in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the period. Finally, Brighton Jones LLC bought a new stake in shares of Glaukos during the second quarter valued at about $208,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

Glaukos Trading Down 0.8 %

Shares of NYSE GKOS opened at $142.88 on Tuesday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $146.86. The company has a market cap of $7.88 billion, a price-to-earnings ratio of -47.31 and a beta of 1.02. The business has a fifty day simple moving average of $132.40 and a 200-day simple moving average of $123.80.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.50) earnings per share. Sell-side analysts predict that Glaukos Co. will post -1.96 EPS for the current year.

Analyst Ratings Changes

GKOS has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Truist Financial boosted their target price on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Piper Sandler set a $140.00 target price on Glaukos in a research report on Thursday, October 17th. BTIG Research lifted their price target on Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Finally, Needham & Company LLC upped their price objective on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $134.55.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.